Autoantibody-mediated atherosclerosis

Autoimmunity Reviews

Volumn 1, Issue 6, 2002, Pages 348-353

  Matsuura, Eiji ^a   Kobayashi, Kazuko ^a   Koike, Takao ^b   Shoenfeld, Yehuda ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

2 Glycoprotein; Anti 2 glycoprotein I antibody; Antiphospholipid syndrome; Autoantibody; Macrophage; Oxidized LDL

Indexed keywords

7 KETOCHOLESTEROL 9 CARBOXYNONANOATE; 9 OXO 9 (7 KETOCHOLEST 5 EN 3BETA YLOXY)NONANOIC ACID; AUTOANTIBODY; BETA 2 GLYCOPROTEIN 1 AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CHOLESTEROL DERIVATIVE; CHOLESTEROL LINOLEATE; FC RECEPTOR; LIGAND; LINOLENIC ACID; LIPOSOME; LOW DENSITY LIPOPROTEIN ANTIBODY; NONANOIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; REVIEW; THROMBOSIS; ARTERIOSCLEROSIS; BIOLOGICAL MODEL; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ARTERIOSCLEROSIS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS; LIGANDS; LIPOPROTEINS, LDL; MODELS, CARDIOVASCULAR;

EID: 0037802819     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(02)00084-8     Document Type: Review

References (36)

1. Boey M.L., Colaco C.B., Gharavi A.E., Elkon K.B., Loizou S., Hughes G.R.V. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulation lupus anticoagulant. Br Med J. 287:1983;1021-1023.
2. Harris E.N., Gharavi A.E., Boey M.L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2:1983;1211-1214.
3. Hughes G.R.V., Harris E.N., Gharavi A.E. The anticardiolipin syndrome. J Rheumatol. 13:1986;486-489.
4. Galli M., Comfurius P., Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547.
5. 2- glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 87:1990;4120-4124.
6. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 336:1990;177-178.
7. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 39:1996;1466-1474.
8. Alarcon-Segovia D., Cabral A.R. The concept and classification of antiphospholipid/cofactor syndromes. Lupus. 5:1996;364-367.
9. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 179:1994;457-462.
10. O'Brien K.D., Alpers C.E., Hokanson J.E., Wang S., Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation. 94:1996;1216-1225.
11. 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 107:1997;569-573.
12. 2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res. 42:2001;697-709.
13. Esterbauer H., Jurgens G., Quehenberger O., Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res. 28:1987;495-509.
14. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell. 93:1998;229-240.
15. 2. Arterioscler Thromb Vasc Biol. 15:1995;1131-1138.
16. Kritharides L., Jessup W., Gifford J., Dean R.T. A method for defining the stages of low density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal Biochem. 213:1993;79-89.
17. van Heek M., Schmitt D., Toren P., Cathcart M.K., DiCorleto P.E. Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivated platelet-derived growth factor. J Biol Chem. 273:1998;19405-19410.
18. Brown A.J., Leong S.L., Dean R.T., Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res. 38:1997;1730-1745.
19. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 142:1999;1-28.
20. Kamido H., Kuksis A., Marai L., Myher J.J. Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein. FEBS Lett. 304:1992;269-272.
21. Kamido H., Kuksis A., Marai L., Myher J.J. Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. J Lipid Res. 36:1995;1876-1886.
22. Hoppe G., Ravandi A., Herrera D., Kuksis A., Hoff H.F. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins and are present in human atherosclerotic lesions. J Lipid Res. 38:1997;1347-1360.
23. Griffith R.L., Virella G.T., Stevenson H.C., Lopes-Virella M.F. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes; a possible mechanism of foam cell formation. J Exp Med. 168:1988;1041-1059.
24. Lopes-Virella M.F., Binzafar N., Rackley S., Takei A., La Via M., Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor. Atherosclerosis. 135:1997;161-170.
25. Khoo J.C., Miller E., Pio F., Steinberg D., Witztum J.L. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb. 12:1992;1258-1266.
26. Kiener P.A., Rankin B.M., Davis P.M., Yocum S.A., Warr G.A., Grove R.I. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol. 15:1995;990-999.
27. Morganelli P.M., Rogers R.A., Kitzmiller T.J., Bergeron A. Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors. J Lipid Res. 36:1995;714-724.
28. Palinski W., Rosenfeld M.E., Yla-Herttuala S., et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
29. Palinski W., Yla-Harttuala S., Rosenfeld M.E., et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosclerosis. 10:1990;325-335.
30. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidized LDL and progression of carotide atherosclerosis. Lancet. 339:1992;883-887.
31. Puurunen M., Vaarala O., Julkunen H., Aho K., Palosuo T. Antibodies to phospholipid binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 80:1996;16-22.
32. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 341:1993;923-925.
33. 2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br J Rheumatol. 37:1998;746-749.
34. 2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol. 37:1998;883-888.
35. 2-glycoprotein I. Circulation. 98:1998;1108-1115.
36. 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 99:1999;2227-2230.